SNS-032

DB05969InvestigationalSmall molecule

Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and solid tumors.

Chemical structure of SNS-032
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and solid tumors.Curator reviewed
Formula / weight
C17H24N4O2S2 · 380.53 g/mol (avg)
Code names
SNS-032

Resolves to

Structure
InChIKeyOUSFTKFNBAZUKL-UHFFFAOYSA-NSMILESCC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
25+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with SNS-032, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account